Share on StockTwits

Edwards Lifesciences Corp (NYSE:EW) VP Patrick B. Verguet sold 7,800 shares of the company’s stock on the open market in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $95.50, for a total value of $744,900.00. Following the completion of the transaction, the vice president now directly owns 49,053 shares in the company, valued at approximately $4,684,562. The sale was disclosed in a legal filing with the SEC, which is available at this link.

A number of research firms have recently commented on EW. Analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences Corp from $78.00 to $90.00 in a research note on Thursday, July 31st. Finally, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Edwards Lifesciences Corp presently has an average rating of “Buy” and an average price target of $90.06.

Shares of Edwards Lifesciences Corp (NYSE:EW) opened at 96.58 on Monday. Edwards Lifesciences Corp has a one year low of $60.62 and a one year high of $97.26. The stock has a 50-day moving average of $89.32 and a 200-day moving average of $79.53. The company has a market cap of $10.241 billion and a price-to-earnings ratio of 13.94. Edwards Lifesciences Corp also was the recipient of a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 2,915,578 shares, a decrease of 45.6% from the July 15th total of 5,356,970 shares. Approximately 2.8% of the shares of the stock are sold short. Based on an average trading volume of 1,687,462 shares, the days-to-cover ratio is presently 1.7 days.

Edwards Lifesciences Corp (NYSE:EW) last released its earnings data on Tuesday, July 29th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp will post $3.29 EPS for the current fiscal year.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.